|
See related Zometa infusion information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Zoledronic acid |
|
Indications |
Treatment of osteolytic, osteoblastic & mixed bone metastases of solid tumors & osteolytic lesions of multiple myeloma in conjunction w/ standard antineoplastic therapy. Reduction of bone damage in patients w/ advanced malignancies involving bone. Treatment of hypercalcaemia of malignancy (HCM).
Click to view Zometa detailed prescribing infomation |
|
Dosage |
IV infusion of no <15 min Adult & elderly Treatment of bone mestastases & osteolytic lesions & reduction of bone damage in patients w/ advanced malignancies involving bone 4 mg every 3-4 wk. Administer oral Ca supplement of 500 mg & vit D 400 IU daily. Treatment of HCM 4 mg.
Click to view Zometa detailed prescribing infomation |
|
Overdosage |
View Zometa overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity to bisphosphonates. Pregnancy & lactation.
Click to view Zometa detailed prescribing infomation |
|
Special Precautions |
Severe renal or hepatic impairment. Monitor serum Ca, phosphate, Mg & creatinine. Ensure adequate hydration. Avoid invasive dental procedures in patients w/ concomitant risk factors (eg cancer, chemotherapy, corticosteroids, poor oral hygiene) due to risk of osteonecrosis of the jaw.
Click to view Zometa detailed prescribing infomation |
|
Adverse Drug Reactions |
Anemia, headache, conjunctivitis, nausea, vomiting, anorexia, bone pain, myalgia, arthalgia, generalized pain, renal impairment, fever, flu-like syndrome, hypophosphatemia, increased blood creatinine & blood urea, hypocalcemia, local infusion site reactions, osteonecrosis of the jaw.
View ADR Monitoring Form |
|
Drug Interactions |
Aminoglycosides, other potentially nephrotoxic drugs, thalidomide.
View more drug interactions with Zometa |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Zometa detailed prescribing infomation |
|
Storage |
View Zometa storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Zometa description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Zometa mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Zometa infusion |
|
Zometa 4 mg/5 mL x 1's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig |
|
|
|
|
